UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011612
Receipt number R000013584
Scientific Title Evaluation of Amyloid Imaging in People with Metabolic Disorder Identified by Brain FDG-PET as Part of a Complete Medical Checkup
Date of disclosure of the study information 2013/10/01
Last modified on 2018/09/04 09:19:28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of Amyloid Imaging in People with Metabolic Disorder Identified by Brain FDG-PET as Part of a Complete Medical Checkup

Acronym

Amyloid Imaging in Medical Checkup

Scientific Title

Evaluation of Amyloid Imaging in People with Metabolic Disorder Identified by Brain FDG-PET as Part of a Complete Medical Checkup

Scientific Title:Acronym

Amyloid Imaging in Medical Checkup

Region

Japan


Condition

Condition

Alzheimer disease

Classification by specialty

Neurology Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this research is to establish evidence on the usefulness of amyloid PET and brain FDG-PET in the preclinical diagnosis of AD. People who have abnormal metabolism identified by FDG-PET will undergo amyloid PET, detailed cognitive function tests, symptom assessments and other examinations. Those who have abnormal metabolism on an FDG-PET scan and positive amyloid PET (stage 2 preclinical AD) and those who have abnormal metabolism on an FDG-PET scan and normal amyloid PET (which may represent non-preclinical AD but suggest other neurological disease) will be monitored for a long term to assess changes in clinical features and cognitive function over time.

Basic objectives2

Bio-availability

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Each 30 subjects who have abnormal metabolism on an FDG-PET scan and positive amyloid PET (stage 2 preclinical AD) and those who have abnormal metabolism on an FDG-PET scan and normal amyloid PET (which may represent non-preclinical AD but suggest other neurological disease) will be monitored for a long term to assess changes in clinical features and cognitive function over time.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The study population will consist of people who have a special cancer screening (whole-body FDG-PET) at the Preventive Medicine Center and consent to undergo cognitive function tests and brain FDG-PET.

Key exclusion criteria

Disagree

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Koji Murakami

Organization

School of medicine, Keio University

Division name

Department of radiology,

Zip code


Address

35 Shinanomachi, Shinjuku-ku, Tokyo

TEL

+81-3-3353-1211

Email

kjmuraka@z3.keio.jp


Public contact

Name of contact person

1st name
Middle name
Last name Daisuke Ito

Organization

School of medicine, Keio University

Division name

Department of neurology

Zip code


Address

35 Shinanomachi, Shinjuku-ku, Tokyo

TEL

+81-3-5363-3788

Homepage URL


Email

d-ito@jk9.so-net.ne.jp


Sponsor or person

Institute

School of medicine, Keio University

Institute

Department

Personal name



Funding Source

Organization

Piramal

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

India


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results

Amyloid PET negaitve

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 08 Month 22 Day

Date of IRB


Anticipated trial start date

2014 Year 01 Month 01 Day

Last follow-up date

2016 Year 08 Month 31 Day

Date of closure to data entry

2017 Year 05 Month 01 Day

Date trial data considered complete

2017 Year 05 Month 01 Day

Date analysis concluded

2017 Year 05 Month 01 Day


Other

Other related information

1.Amyloid PET (AV1)
2.Brain FDG-PET
3.Brief cognitive function tests (MMSE, CDT and MOCA)
4.Assessments of symptoms and insight (e.g., UPDRS, NPI and GDS)
5.Cognitive function assessments (RCPM,RAVLT,ROCFT,WMS-R,Trail Making Test,Stroop Test,Word fluency)


Management information

Registered date

2013 Year 08 Month 31 Day

Last modified on

2018 Year 09 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013584


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name